What is the ticker symbol for CymaBay Therapeutics?

CymaBay Therapeutics trades under the ticker CBAY on NASDAQ.

What sector does CymaBay Therapeutics operate in?

CymaBay Therapeutics is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze CBAY in a portfolio?

PortView shows CBAY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

CymaBay Therapeutics (CBAY) Stock Analysis

NASDAQHealthcareBiotechnology

$32.48+0.03%

1-year price historyRange $7.47 – $32.48

52-week range$32.48

$7.26$32.50

What CymaBay Therapeutics does

CymaBay Therapeutics, Inc. is a biopharmaceutical company in the clinical development phase, focused on discovering and delivering treatments for liver disorders and various other long-term illnesses. A key experimental therapy in their portfolio is seladelpar (MBX-8025), a selective activator of the peroxisome proliferator activated receptor delta. This compound is currently undergoing a pivotal Phase III clinical trial for primary biliary cholangitis (PBC), and has also concluded a Phase 2b study investigating its use for nonalcoholic steatohepatitis (NASH). Additionally, the company is advancing MBX-2982 through Phase 2a clinical trials, aiming to address hypoglycemia in individuals with type 1 diabetes. CymaBay maintains strategic partnerships, including a licensing arrangement with ABW Cyclops SPV LP to aid the development of seladelpar for PBC. They also possess a global license from Janssen Pharmaceuticals, Inc. to research, develop, and bring to market compounds active against an undisclosed metabolic disease target. Established in 1988 and formerly known as Metabolex, Inc., CymaBay Therapeutics, Inc. is headquartered in Newark, California.

Key metrics

Market cap

$3.73B

P/E (TTM)

-32.81

EPS (TTM)

$-0.99

Beta

0.32

Dividend yield

0.00%

Revenue / share

$0.29

50-day avg

$28.59

200-day avg

$18.42

52-week high

$32.50

52-week low

$7.26

CEO

Sujal A. Shah

ETFs linked to CBAY

Broad-market and Healthcare sector ETFs an investor holding CymaBay Therapeutics is often also exposed to. Open an ETF page to see its actual top holdings.

SPY — SPDR S&P 500 ETF Trust VOO — Vanguard S&P 500 ETF QQQ — Invesco QQQ Trust VTI — Vanguard Total Stock Market ETF

PortView Portfolio Insights

PortView analyzes how CBAY fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Analyze CBAY in PortView →

Similar companies

JNJ — Johnson &LLY — Eli Lilly A — Agilent Technologies ABBV — AbbVie Inc.ABT — Abbott Laboratories ALNY — Alnylam Pharmaceuticals

Frequently asked questions

What is the ticker symbol for CymaBay Therapeutics?: CymaBay Therapeutics trades under the ticker CBAY on NASDAQ.
Which exchange is CBAY listed on?: CBAY is listed on NASDAQ.
What sector does CymaBay Therapeutics operate in?: CymaBay Therapeutics is classified in the Healthcare sector (Biotechnology industry).
How can PortView help analyze CBAY in a portfolio?: PortView shows CBAY's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.

The information provided by PortView is for informational and educational purposes only and does not constitute investment advice. Market data may be delayed. Past performance does not guarantee future results.